These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16302797)

  • 1. 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.
    Wissner A; Floyd MB; Johnson BD; Fraser H; Ingalls C; Nittoli T; Dushin RG; Discafani C; Nilakantan R; Marini J; Ravi M; Cheung K; Tan X; Musto S; Annable T; Siegel MM; Loganzo F
    J Med Chem; 2005 Dec; 48(24):7560-81. PubMed ID: 16302797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
    Wissner A; Fraser HL; Ingalls CL; Dushin RG; Floyd MB; Cheung K; Nittoli T; Ravi MR; Tan X; Loganzo F
    Bioorg Med Chem; 2007 Jun; 15(11):3635-48. PubMed ID: 17416531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
    Kuo GH; Prouty C; Wang A; Emanuel S; Deangelis A; Zhang Y; Song F; Beall L; Connolly PJ; Karnachi P; Chen X; Gruninger RH; Sechler J; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
    J Med Chem; 2005 Jul; 48(15):4892-909. PubMed ID: 16033269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.
    Borzilleri RM; Bhide RS; Barrish JC; D'Arienzo CJ; Derbin GM; Fargnoli J; Hunt JT; Jeyaseelan R; Kamath A; Kukral DW; Marathe P; Mortillo S; Qian L; Tokarski JS; Wautlet BS; Zheng X; Lombardo LJ
    J Med Chem; 2006 Jun; 49(13):3766-9. PubMed ID: 16789733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold.
    Kissau L; Stahl P; Mazitschek R; Giannis A; Waldmann H
    J Med Chem; 2003 Jul; 46(14):2917-31. PubMed ID: 12825933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
    Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL
    J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
    Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
    J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.
    Kuo GH; Wang A; Emanuel S; Deangelis A; Zhang R; Connolly PJ; Murray WV; Gruninger RH; Sechler J; Fuentes-Pesquera A; Johnson D; Middleton SA; Jolliffe L; Chen X
    J Med Chem; 2005 Mar; 48(6):1886-900. PubMed ID: 15771433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.
    Dai Y; Guo Y; Frey RR; Ji Z; Curtin ML; Ahmed AA; Albert DH; Arnold L; Arries SS; Barlozzari T; Bauch JL; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Guo J; Li J; Marcotte PA; Marsh KC; Moskey MD; Pease LJ; Stewart KD; Stoll VS; Tapang P; Wishart N; Davidsen SK; Michaelides MR
    J Med Chem; 2005 Sep; 48(19):6066-83. PubMed ID: 16162008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas.
    Kubo K; Shimizu T; Ohyama S; Murooka H; Iwai A; Nakamura K; Hasegawa K; Kobayashi Y; Takahashi N; Takahashi K; Kato S; Izawa T; Isoe T
    J Med Chem; 2005 Mar; 48(5):1359-66. PubMed ID: 15743179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.
    Kiselyov AS; Semenova M; Semenov VV; Piatnitski E
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1726-30. PubMed ID: 16364640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1-(Azolyl)-4-(aryl)-phthalazines: novel potent inhibitors of VEGF receptors I and II.
    Kiselyov AS; Semenova M; Semenov VV; Piatnitski EL
    Chem Biol Drug Des; 2006 Nov; 68(5):250-5. PubMed ID: 17177884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors.
    Peifer C; Stoiber T; Unger E; Totzke F; Schächtele C; Marmé D; Brenk R; Klebe G; Schollmeyer D; Dannhardt G
    J Med Chem; 2006 Feb; 49(4):1271-81. PubMed ID: 16480264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.
    Harris PA; Cheung M; Hunter RN; Brown ML; Veal JM; Nolte RT; Wang L; Liu W; Crosby RM; Johnson JH; Epperly AH; Kumar R; Luttrell DK; Stafford JA
    J Med Chem; 2005 Mar; 48(5):1610-9. PubMed ID: 15743202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
    La DS; Belzile J; Bready JV; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn JC; Flynn SR; Graceffa RF; Harriman SP; Larrow JF; Long AM; Martin MW; Morrison MJ; Patel VF; Roveto PM; Wang L; Weiss MM; Whittington DA; Teffera Y; Zhao Z; Polverino AJ; Harmange JC
    J Med Chem; 2008 Mar; 51(6):1695-705. PubMed ID: 18311900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent.
    Hudkins RL; Becknell NC; Zulli AL; Underiner TL; Angeles TS; Aimone LD; Albom MS; Chang H; Miknyoczki SJ; Hunter K; Jones-Bolin S; Zhao H; Bacon ER; Mallamo JP; Ator MA; Ruggeri BA
    J Med Chem; 2012 Jan; 55(2):903-13. PubMed ID: 22148921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.
    Potashman MH; Bready J; Coxon A; DeMelfi TM; DiPietro L; Doerr N; Elbaum D; Estrada J; Gallant P; Germain J; Gu Y; Harmange JC; Kaufman SA; Kendall R; Kim JL; Kumar GN; Long AM; Neervannan S; Patel VF; Polverino A; Rose P; Plas Sv; Whittington D; Zanon R; Zhao H
    J Med Chem; 2007 Sep; 50(18):4351-73. PubMed ID: 17696416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-Hydroxy-4,6-diamino-[1,3,5]triazines: a novel class of VEGF-R2 (KDR) tyrosine kinase inhibitors.
    Baindur N; Chadha N; Brandt BM; Asgari D; Patch RJ; Schalk-Hihi C; Carver TE; Petrounia IP; Baumann CA; Ott H; Manthey C; Springer BA; Player MR
    J Med Chem; 2005 Mar; 48(6):1717-20. PubMed ID: 15771417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases.
    Thompson AM; Delaney AM; Hamby JM; Schroeder MC; Spoon TA; Crean SM; Showalter HD; Denny WA
    J Med Chem; 2005 Jul; 48(14):4628-53. PubMed ID: 16000000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.